How to differentiate benign from malignant bile duct strictures?

	Tweet

The main etiology of bile duct strictures closely related to the liver is a malignancy (cancer). However, the differentiation of benign and malignant strictures is notoriously difficult. The consequences for the patient are considerable because cancer in this anatomical location requires extensive surgery with removal of a large part of the liver. Extensive work-up including multi-slice computed tomography (CT), colour Doppler ultrasonography and magnetic resonance imaging (MRI) may improve the diagnostic dilemma. However, up to date, no single investigation reliably differentiates malignant from benign bile duct strictures.

A research article to be published on August 28, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Prof. van Gulik from the Surgical Department, analyzed a patient cohort that underwent resection for presumed malignancy of the bile duct, during the period 1998 to 2006. The final histologic diagnosis of 68 patients was correlated with the preoperative clinical, laboratory and radiological findings. Fifteen percent patients were found to have a benign lesion.

The findings of the different imaging studies revealed that only one feature, i.e. involvement of the blood vessels, showed a significant association with malignany. All other features including clinical presentation, laboratory tests, brush cytology, and other imaging studies were unable to differentiate malignant and benign strictures.

Invasion of the blood vessels was based on the findings of colour Doppler ultrasonography defined as an increase of flow compatible with stenosis, or absence of flow compatible with occlusion. Furthermore, vascular involvement was identified on contrast enhanced CT as vascular stenosis or occlusion of the portal vein and/or the hepatic artery. In 21 patients, the portal vein and/or branches of the hepatic artery were involved in the tumor process, and all these patients were finally diagnosed to have a malignant lesion.

Despite using recent, state-of-the-art imaging modalities, 15% patients with presumed malignancy underwent an extensive operation but were ultimately diagnosed to have benign strictures. Due to the relatively low incidence of vascular involvement (31% in this series), the absence of this finding is not conclusive. The article demonstrates that the differentiation of bile duct strictures remains difficult and that more research is needed to solve this diagnostic problem.

###

Contact: Lai-Fu Li

86-105-908-0039
World Journal of Gastroenterology

RELATED STORIES:
Eating mandarins reduces the risk of liver disease, hardened arteries and insulin resistance   Racial disparities evident in early-stage liver cancer survival   Liver cancer incidence lower in patients with nonalcoholic fatty liver disease than hepatitis C   A promising molecular target for liver cancer therapy   Liver transplant recipients almost 3 times more likely to develop cancer   Liver Tumors Associated with Metabolic Syndrome Differ from Other Tumors   The relationship between body mass index and age at hepatocellular carcinoma onset   Research in fish provides new clues about deadly form of liver cancer   Metformin May Protect Against Liver Cancer   Proton beams control liver tumors   Omega-3 fatty acids inhibit the growth of liver cancer cells   Experts find rogue stem cells in liver cancer   Liver cancer is likely caused by cycles of liver cell death and renewal   Sex hormone explains men’s higher liver cancer risk   New study confirms link between nonalcoholic steatohepatitis and liver cancer   New Technique in Treating Patients With Liver Cancer Proves Effective   Personalized treatment may help some liver cancer patients   Liver cancer in cirrhotic patients effectively treated with radiofrequency ablation   Blacks with Liver Cancer More Likely to Die   Wilmot Researchers Create New Way to Study Liver Cancer   Saffron shows promise in preventing liver cancer   Cycles of Cell Death, Proliferation Key to Liver Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]